Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 | P03956 | 1/20 | 0.48 |
| ▸ | MMP2 | P08253 | 1/20 | 0.48 |
| ▸ | MMP3 | P08254 | 1/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15116453 | 1.00 | MMP1 (0.48) | MMP1MMP2MMP3CA12CA1 | |
| SCHEMBL16359203 | 1.00 | MMP1 (0.48) | MMP1MMP2MMP3CA12CA1 | |
| SCHEMBL5907648 | 0.84 | MMP1 (0.47) | MMP1MMP2MMP3CA12CA1 | |
| SCHEMBL18993862 | 0.84 | MMP1 (0.47) | MMP1MMP2MMP3CA12CA1 | |
| SCHEMBL16217739 | 0.82 | MMP1 (0.45) | MMP1MMP2MMP3CA12CA1 | |
| SCHEMBL11890388 | 0.81 | LMNA (0.53) | MMP1MMP2CA12CA1CA2 | |
| SCHEMBL15116476 | 0.81 | PSMB5 (0.46) | SMN1; SMN2GAAACACBHPGDALDH1A1 | |
| SCHEMBL11890364 | 0.81 | MME (0.43) | CA2SMN1; SMN2GAAACACBHPGD | |
| SCHEMBL7604693 | 0.80 | — | — | |
| SCHEMBL875553 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | GEORGETOWN UNIVERSITY (US) | 2026-03-26 | — | — | US | disclosed |
| WO-2023069721-A2 | OXAZOLE, OXADIAZOLE, AND INDOLE DERIVATIVES FOR THE INHIBITION OF USP28 | CARMOT THERAPEUTICS, INC. (US) | 2023-04-27 | — | — | WO | disclosed |
| WO-2021067738-A1 | DEVELOPMENT OF IMAGING AND THERAPEUTIC GLUCOSE ANALOGUES FOR SODIUM DEPENDENT GLUCOSE TRANSPORTERS | UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (US) | 2021-04-08 | — | — | WO | disclosed |
| US-20190125701-A1 | Compositions and Methods for Treating Viral Infection in Mammals | UNIV YALE (US) | 2019-05-02 | — | — | US | disclosed |
| EP-3452172-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS | Yale University (US) | 2019-03-13 | — | — | EP | disclosed |
| WO-2017192799-A1 | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTION IN MAMMALS | YALE UNIVERSITY (US) | 2017-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260083724-A1 | COMPOUNDS TARGETING PAX3::FOXO1 FUSION PROTEIN | PAX3, FOXO1, PAXBP1 | MMP1 1315/4885MMP2 1287/4885MMP3 2685/4885 |
| US-20190125701-A1 | Compositions and Methods for Treating Viral Infection in Mammals | RPL35, PIGS, HAVCR2 | MMP1 1275/4885MMP2 2410/4885MMP3 1798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.